<DOC>
	<DOC>NCT00642733</DOC>
	<brief_summary>This single arm study will assess the efficacy and safety of Tarceva + gemcitabine in patients with locally advanced, unresectable or metastatic pancreatic cancer. Patients will receive Tarceva 100mg po daily, in combination with gemcitabine 1000mg/m2 iv weekly for 8 weeks, followed by weekly for 3 weeks of each 4 week cycle. The anticipated time on study treatment is until disease progression, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; pancreatic cancer, surgically unresectable or with metastases; no previous chemotherapy (except concomitant with radiotherapy); ECOG 02. pancreatic cancer without histologic or cytologic confirmation; surgical resection possible; previous chemotherapy not concomitant with radiotherapy; ECOG 34.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>